Loading
Yearly MRI or endoscopic ultrasound for people with inherited risk, which catches pancreatic cancers while they are still operable.
The Cancer of the Pancreas Screening (CAPS) consortium and the PRECEDE consortium (>50 centres) follow carriers of BRCA2, PALB2, ATM, CDKN2A, STK11, Lynch genes, and familial pancreatic cancer kindreds with annual MRI/MRCP or EUS. In CAPS5 (2022), 77% of screen-detected cancers were stage I versus ~15% in the general population, with 5-year survival ~73%. Blood tests (CA19-9 glycan variants, MCED) and AI on prior CTs aim to extend surveillance to new-onset diabetes and other higher-risk groups.
Annual cross-sectional imaging of the pancreas in a population with 5-10x baseline risk; resection of high-grade precursor lesions and early cancers.
The current honest statement of where early detection stands: no blood test is ready, and the research is about finding the threshold at which to operate.
The stage shift the pancreatic cancer page quotes (about three in four surveillance-detected cancers at stage I) and the strongest argument for offering surveillance to every germline carrier found by universal testing, which the NHS does not yet do outside research.
PRECEDE is the infrastructure answer to CAPS's problem: no single centre can enrol enough high-risk people to validate an early detection test.
It gives surveillance a target and a timetable: catch high-grade dysplasia and there are about three years before invasion, and TGF-beta pathway loss is the event to detect.
The rulebook behind the CAPS cohorts and the UK EUROPAC programme; it is also the reason surveillance for carriers is not yet a routine NHS service, because the consortium itself asked for it to stay within research until benefit was shown.
Family history misses most carriers, so the NCCN and ASCO guidelines moved to testing every patient; each carrier found is a family that can be offered surveillance and a patient who may be eligible for platinum and PARP inhibition.
A scoring tool that needs no new test and can run in primary care records; it turns the 1 percent of Chari's cohort into a 3.6 percent group in whom imaging or a blood test becomes defensible.
It reframes multifocal high-grade dysplasia found at surveillance: the pancreas may hold one spreading lesion rather than several, which bears on how much gland to remove.
Query for this technology: (TITLE:"High-risk pancreatic surveillance" OR ABSTRACT:"High-risk pancreatic surveillance" OR TITLE:"CAPS / PRECEDE" OR ABSTRACT:"CAPS / PRECEDE") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about High-risk pancreatic surveillance (CAPS / PRECEDE), not a curated reading list.
Shares Recommendations for a more organized and effective approach to the early detection of pancreatic cancer from the PRECEDE (Pancreatic Cancer Early Detection) consortium, Pancreatic cancer early detection biomarkers for high-risk individuals: insights from the PRECEDE consortium, Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium, Intraductal papillary mucinous neoplasm and other pancreatic cystic precursors.
Shares Blood-based pancreatic cancer detection in new-onset diabetes, Model to Determine Risk of Pancreatic Cancer in Patients With New-Onset Diabetes, Run the ENDPAC score on every new diabetes diagnosis after 50 and scan the high scorers, Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question.
Shares Model to Determine Risk of Pancreatic Cancer in Patients With New-Onset Diabetes, Run the ENDPAC score on every new diabetes diagnosis after 50 and scan the high scorers, CA 19-9, Multi-cancer early detection (MCED).
Shares New-onset diabetes as a signal of pancreatic cancer (and the ENDPAC score), Blood-based pancreatic cancer detection in new-onset diabetes, Model to Determine Risk of Pancreatic Cancer in Patients With New-Onset Diabetes, Run the ENDPAC score on every new diabetes diagnosis after 50 and scan the high scorers.
Shares CAPS: the Cancer of the Pancreas Screening consortium and its surveillance studies (CAPS1 to CAPS5), High-risk stigmata and worrisome features of pancreatic cysts (IPMN and MCN surgical criteria), Familial pancreatic cancer and inherited risk (who qualifies for surveillance), Invasive carcinoma arising in an intraductal papillary mucinous neoplasm (IPMN-associated carcinoma).
Shares High-risk stigmata and worrisome features of pancreatic cysts (IPMN and MCN surgical criteria), Colloid (mucinous non-cystic) carcinoma of the pancreas, Invasive carcinoma arising in an intraductal papillary mucinous neoplasm (IPMN-associated carcinoma), Intraductal papillary mucinous neoplasm and other pancreatic cystic precursors.
Shares New-onset diabetes as a signal of pancreatic cancer (and the ENDPAC score), Intraductal papillary mucinous neoplasm and other pancreatic cystic precursors, MRI, The hardest cancers are found late.
Shares Run the ENDPAC score on every new diabetes diagnosis after 50 and scan the high scorers, Surveillance for every germline carrier found by universal testing, inside a registry rather than a research exception, Stage shift, Intraductal papillary mucinous neoplasm and other pancreatic cystic precursors.